Therapeutic product candidates
Multiple sclerosis (MS) is a chronic, inflammatory condition of the nervous system and is the most common, non-traumatic, disabling neurological disease in young adults, with most sufferers developing the disease between the ages of 20 and 40.
The World Health Organization estimates that up to 2.5 million people suffer from MS worldwide. Women are affected 1.8 times more frequently than men. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination.
MS develops as a result of damage to the myelin sheath of the nerves which interferes with their normal function and leads to loss of muscle control. MS can either be progressive or be characterised by periods of relapse and remission; the unpredictable nature of the disease makes life very hard for patients. The relapsing forms of MS are the most common.
Apitope’s lead product candidate is ATX-MS-1467, a potentially disease-modifying therapy for the treatment of MS.
ATX-MS-1467 is a novel peptide-based therapeutic derived from Apitope’s proprietary technology platform. It is designed to target up to 70% of MS patients who have a specific genetic profile.
It consists of four short peptides that are derived from myelin basic protein, a key autoantigen in MS. It is designed to induce immunological tolerance of the body’s T cells to key autoantigens thought to be involved in the pathogenesis of MS. This peptide therapeutic has completed an initial clinical studies in six patients with secondary progressive MS and has since advanced to phase II of clinical development.
The figure below illustrates the powerful effect of Apitope® treatment in an experimental autoimmune encephalomyelitis (EAE) model compared to Copaxone treatment and a PBS control
Dellovade T., Rudin S., Zozulya A. and Tomkinson B., ATX-MS-1467, An Immunotolerizing Agent, Halts Disease Progression and Reduces CNS Inflammation in Rodent Models of Multiple Sclerosis (P1.216). Neurology (2014) 82: 10 Supplement P1.216